JPMorgan cuts Alnylam stock price target on Amvuttra forecast
JPMorgan reduced its price target for Alnylam Pharmaceuticals (ALNY) to $254 from $369, citing lowered Amvuttra revenue forecasts. The stock has fallen 61% YTD. The firm expects 2027 guidance in February. Alnylam announced a $1B stock repurchase program. Multiple analysts have adjusted targets downward, citing execution risks and slower demand.
How this was made
The 30-second read
Why it matters
The forecast reduction (2026-2030 revenue down 2% to 21%) and the PT cut from $369 to $254 are concrete valuation inputs that can drive incremental positioning, especially given the stock’s large YTD drawdown.
Market read
A specific sell-side forecast reset for Amvuttra plus a large PT reduction provides a fresh catalyst for traders managing biotech valuation and near-term expectation risk.
What to watch
The article also mentions a $1B repurchase program and a shift in when 2027 guidance will be provided, which could support sentiment and reduce near-term information risk.
Background
The piece centers on JPMorgan’s model review for Alnylam’s Amvuttra and expectation resets tied to early launch demand composition and Part B reimbursement under 340b.
Ticker impact
JPMorgan cut Alnylam’s Amvuttra revenue forecasts for 2026-2030 and lowered its price target to $254 while keeping an Overweight rating.
Likely downward pressure as the market reprices Amvuttra demand and reimbursement uncertainty reflected in the forecast reset.
The article discloses a specific analyst model change (revenue forecast reduction) plus a large PT cut, alongside expectation resets tied to launch momentum and 340b reimbursement changes.
Market effects
Biopharma investors may further scrutinize launch momentum and reimbursement dynamics for specialty therapies, affecting sentiment across similar commercial-stage names.
Primarily US biotech sentiment, with read-through to NASDAQ biotech risk appetite.
Limited direct global impact beyond broader risk appetite for commercial-stage rare-disease and specialty pharma.
Counterpoint
Despite the PT cut, JPMorgan maintained Overweight, implying the valuation still offers upside if 2027 guidance and demand normalize.
Key entities
- companyAlnylam Pharmaceuticals
NASDAQ-listed biotech subject of JPMorgan’s Amvuttra forecast review and price-target cut.
- productAmvuttra
Alnylam therapy whose revenue forecasts were reduced due to revised launch and reimbursement assumptions.
- analyst_firmJPMorgan
Brokerage that lowered the price target and adjusted forecast assumptions while keeping Overweight.


